Covid Vaccine: government likely to buy another 4.5 crore doses of Covidshield Vaccine by April

The government on Wednesday said that it is committed to buying from the Serum Institute further 4.5 crore doses of Oxford Covid-19 vaccine, Covishield, at a price of Rs 200 per shot plus applicable taxes by April, in addition to a firm order given to the company for 1.1 crore doses. From Tuesday morning onwards, […]

Update: 2021-01-12 06:19 GMT

The government on Wednesday said that it is committed to buying from the Serum Institute further 4.5 crore doses of Oxford Covid-19 vaccine, Covishield, at a price of Rs 200 per shot plus applicable taxes by April, in addition to a firm order given to the company for 1.1 crore doses.

From Tuesday morning onwards, flights started ferrying the vaccines to different cities from Pune.

According to the purchase order placed on Monday, each dose of the vaccine has been priced at Rs 200 and with GST of Rs 10, it would cost Rs 210.

The HLL Lifecare Limited, a public sector undertaking, issued the supply orders on behalf of the Union Health Ministry on Monday.

The first order of 1.1 crore doses of Covishield will be worth Rs 231 crore, while the total amount including the commitment for 4.5 crore doses will amount to an estimated Rs 1,176 crore at current rates, according to sources.

The government on Monday also placed an order to Bharat Biotech for 55 lakh doses of indigenously developed Covaxin costing Rs 162 crore.

India had recently approved two vaccines, Oxford’s Covishield manufactured by SII in the country and Bharat Biotech’s Covaxin, for restricted emergency use.

The country will launch its Covid -19 vaccination drive from January 16 in what Prime Minister Narendra Modi has called the world’s largest inoculation programme with priority to be given to nearly three crore healthcare and frontline workers.

According to the Covid-19 Vaccine Operational Guidelines, the shots will be offered first to an estimated one crore healthcare workers, and around two crore frontline workers, and then to persons above 50 years of age, followed by persons younger than 50 years of age with associated comorbidities based on evolving pandemic situation.

Tags:    

Similar News